Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024

Core Viewpoint - Aptose Biosciences Inc. is set to report its financial results for Q4 and the full year of 2023 on March 26, 2024, along with a corporate update [1]. Group 1: Financial Reporting - The financial results will be disclosed after the market closes on March 26, 2024 [1]. - Analysts can participate in a Q&A session by pre-registering for the conference call [3]. Group 2: Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [4]. - The company has a pipeline of small molecule cancer therapeutics aimed at providing single-agent efficacy and enhancing the effectiveness of other anti-cancer therapies without overlapping toxicities [4]. - Two clinical-stage oral kinase inhibitors are under development: tuspetinib (HM43239) for relapsed or refractory acute myeloid leukemia (AML) and luxeptinib (CG-806) for relapsed or refractory hematologic malignancies [4].